MMR deficiency is frequent in colorectal carcinomas with diffuse SLFN11 immunostaining: clinicopathologic and molecular study of 31 cases identified among 3,300 tumors

Abstract Schlafen 11 (SLFN11), a regulator of cell fate following DNA injury, sensitizes tumor cells to DNA‐damaging agents. Patients with SLFN11‐positive tumors may benefit from DNA‐damaging chemotherapies. SLFN11 has been studied in different types of cancer including colorectal carcinomas. Howeve...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Maciej Kaczorowski, Małgorzata Chłopek, Ondřej Daum, Kris Ylaya, Tomáš Vaněček, Magdalena Szczepaniak, Karol Krawczyk, Artur Kowalik, Michal Michal, Jerzy Lasota, Markku Miettinen
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2025-03-01
Rangatū:	The Journal of Pathology: Clinical Research
Ngā marau:	SLFN11 colorectal cancer mismatch repair proteins Lynch syndrome mucinous carcinoma DNA damaging agents
Urunga tuihono:	https://doi.org/10.1002/2056-4538.70025
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!